<DOC>
	<DOCNO>NCT01336049</DOCNO>
	<brief_summary>Nimotuzumab , one new agent use advanced esophageal carcinoma , show effective safe study head-neck cancer . Advanced esophageal carcinoma poor prognosis majority patient resistant chemotherapy China . In investigator phase II clinical trial proceed , combination paclitaxel cisplatin show good tolerance efficacy esophageal carcinoma . The investigator initiate prospective phase II clinical trial Nimotuzumabplus paclitaxel/cisplatin 1st line treatment advance esophageal carcinoma observe efficacy safety combination .</brief_summary>
	<brief_title>Nimotuzumab Plus Paclitaxel Cisplatin 1st Line Treatment Esophageal Squamous Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Having sign informed consent Age 18 75 year old Histologically confirm esophageal squamous carcinoma , Unresectable recurrent metastatic disease , prior palliative chemotherapy ; No prior radiotherapy except radiotherapy nontarget lesion study 3 month , recurrence last adjuvant chemotherapy adjuvant radiotherapy longer 6 month ; prior treatment paclitaxel adjuvant chemotherapy , total dose cisplatin le 300mg/m2 used adjuvant chemotherapy Sex limit Measurable disease accord RECIST criterion ( diameter lesion 10mm spiral CT MRI , 20mm common CT , date image le 15 day enrollment ) Karnofsky performance status ≥80 Life expectancy ≥ 3 month WBC &gt; 4,000/mm3 , absolute neutrophil count ≥2000/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 10g/dl ( within 14 day enrollment ) , ALT AST &lt; 2.5 time ULN ( ≤5 time ULN patient liver metastasis ) , Bilirubin level &lt; 1.0 time ULN , Serum AKP &lt; 2.5 time ULN , Serum creatinine &lt; 1.0 time ULN No sever complication , active gastrointestinal bleeding , perforation , jaundice , obstruction , noncancerous fever ＞ 38℃； Normal ECG heart function Fertile patient must use effective contraception Good compliance Previous treatment palliative chemotherapy recurrence le 6 month time last adjuvant chemo/radiotherapy Known hypersensitivity Nimotuzumab , Paclitaxel , Cisplatin Only Brain bone metastasis Tumor length ≥ 10cm , liver metastasis cover 50 % liver , lung metastasis cover 25 % lung No measurable lesion , eg . pleural fluid ascites Suffer severe heart disease disease important organ Chronic diarrhea renal dysfunction Pregnancy lactation period Other previous malignancy within 5 year , except nonmelanoma skin cancer Chronic diarrhea Mentally abnormal disable cognition , include CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>